IP Library › Granted Patent US 9,611,219
Granted Patent B2
US 9,611,219 · App. 14/381,558 · Granted Apr 4, 2017

Inhibitors of histone demethylases

Inventors: Marc Labelle (Basking Ridge, NJ); Thomas Boesen (København Ø, DK); Mukund Mehrotra (Winnipeg, CA); Qasim Khan (Winnipeg, CA); Farman Ullah (Winnipeg, CA)
Assignee: Gilead Sciences, Inc.
C07D213/79A61K31/44A61K31/443A61K31/444A61K31/4439A61K31/4545A61K31/496C07D401/06C07D401/12C07D405/12C07D413/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,611,219
App. No.
14/381,558
Granted
Apr 4, 2017
Kind
B2
Abstract

The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament. The compounds take the form (I)

Claims (38)

1. A compound according to the formula:

wherein:

R 12 is R 13 O—, wherein R 13 is C 1-4 alkyl;

A is —CHR 2 C(O)—;

Y is —NR 6 R 7 ;

R 1 is —H or methyl;

R 2 is —H, methyl or hydroxymethyl;

Z is a single bond;

each of R 6 and R 7 is independently selected from —H, C 1-8 alkyl, C 1-4 fluoroalkyl, and C 1-4 hydroxyalkyl, wherein alkyl may optionally be substituted with one or more independently selected R 8 ;

each R 8 is independently selected from C 1-6 alkyl, C 1-4 fluoroalkyl, C 1-4 hydroxyalkyl, —Z—NR 10 R 11 , —Z—C(═O)—NR 10 R 11 , —Z—OR 9 , halogen, and —Z—COOR 9 ; and

each R 9 is independently selected from —H and C 1-8 alkyl; and

each R 10 and R 11 is independently selected from —H and C 1-6 alkyl;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein R 13 is selected from methyl, ethyl, and propyl.

3. The compound of claim 1 , wherein Y is

wherein n is from 1 to 3.

4. The compound of claim 3 , wherein Y is

wherein n is from 1 to 3 and each m independently is from 0 to 2.

5. A compound having the structure

or a pharmaceutically acceptable salt thereof.

6. A compound having the structure

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising at least one compound as defined in claim 1 and one or more pharmaceutically acceptable excipients, diluents or carriers.

8. The pharmaceutical composition of claim 7 , comprising one or more further active substances.

9. The compound of claim 1 , wherein R 13 is selected from the group consisting of methyl, ethyl, propyl, and butyl.

10. The compound of claim 1 , wherein R 13 is methyl.

11. The compound of claim 1 , wherein R 13 is ethyl.

12. The compound of claim 1 , wherein R 1 is —H and R 2 is —H.

13. The compound of claim 1 , wherein each of R 6 and R 7 is independently C 1-8 alkyl optionally substituted with one or more independently selected R 8 .

14. The compound of claim 1 , wherein each R 8 is independently —Z—NR 10 R 11 and each R 10 and R 11 is independently C 1-6 alkyl.

15. The pharmaceutically acceptable salt of the compound of claim 6 , wherein the pharmaceutically acceptable salt is selected from a succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, trifluoroacetic, malic, lactic, formic, propionic, glycolic, gluconic, camphorsulfuric, isothionic, mucic, gentisic, isonicotinic, saccharic, glucuronic, furoic, glutamic, ascorbic, anthranilic, salicylic, phenylacetic, mandelic, embonic (pamoic), ethanesulfonic, pantothenic, stearic, sulfinilic, alginic, galacturonic, benzenesulfonic, p-toluenesulfonic, oxalic, methanesulfonic and naphthalenesulfonic acid salt.

16. The pharmaceutically acceptable salt of claim 15 , wherein the pharmaceutically acceptable salt is the oxalic acid salt.

17. The pharmaceutically acceptable salt of the compound of claim 5 , wherein the pharmaceutically acceptable salt is selected from a succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, trifluoroacetic, malic, lactic, formic, propionic, glycolic, gluconic, camphorsulfuric, isothionic, mucic, gentisic, isonicotinic, saccharic, glucuronic, furoic, glutamic, ascorbic, anthranilic, salicylic, phenylacetic, mandelic, embonic (pamoic), ethanesulfonic, pantothenic, stearic, sulfinilic, alginic, galacturonic, benzenesulfonic, p-toluenesulfonic, oxalic, methanesulfonic and naphthalenesulfonic acid salt.

18. The pharmaceutically acceptable salt of claim 17 , wherein the pharmaceutically acceptable salt is the oxalic acid salt.

19. A pharmaceutical composition comprising a compound having the structure:

or a pharmaceutically acceptable salt thereof.

20. A pharmaceutical composition comprising a compound having the structure:

or a pharmaceutically acceptable salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2016
From: EPITHERAPEUTICS, APS
To: GILEAD SCIENCES, INC.
Reel/Frame 039398/0406 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2015
From: LABELLE, MARC; BOESEN, THOMAS; MEHROTRA, MUKUND; KHAN, QASIM; ULLAH, FARMAN
To: EPITHERAPEUTICS APS
Reel/Frame 035277/0789 →
Priority Claims (2)
DK 2012 00599 · Oct 2, 2012 · national
DK 2013 70112 · Feb 27, 2013 · national
Continuity (3)
Provisional Application 61708806 · Oct 2, 2012
Provisional Application 61770050 · Feb 27, 2013
Related Publication 20150203453A1 · Jul 23, 2015